[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100416180":3},{"organization":4,"outcomesModule":7,"designInfo":26,"detailedDescription":27,"studyPopulation":30,"armGroups":31,"interventions":37,"overallOfficials":41,"centralContacts":45,"locations":50,"responsibleParty":68,"collaborators":27,"id":70,"slug":27,"hasResults":71,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":27,"eligibilityCriteria":75,"healthyVolunteers":71,"sex":76,"minAge":77,"maxAge":27,"enrollmentInfo":78,"targetDuration":81,"studyType":82,"phases":27,"briefSummary":83,"conditions":84,"keywords":86,"overallStatus":53,"whyStopped":27,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":97},{"fullName":5,"class":6},"RedDress Ltd.","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":17,"otherOutcomes":22},[9,13],{"measure":10,"description":11,"timeFrame":12},"Percentage area reduction (PAR) at 4 weeks","Change from baseline at 4 weeks of wounds treated with ACTIGRAFT compared to other treatments (no ACTIGRAFT).","4 weeks",{"measure":14,"description":15,"timeFrame":16},"Nature, frequency, and severity of adverse events in the intent to treat population","Nature, frequency, and severity (by CTCAE5) of adverse events","1 year",[18],{"measure":19,"description":20,"timeFrame":21},"Percentage area reduction at 8 and 12 weeks","Change from baseline at 8 and 12 weeks of wounds treated with ACTIGRAFT compared to other treatments (no ACTIGRAFT).","12 weeks",[23],{"measure":24,"description":25,"timeFrame":12},"Reduction in pain at 4 weeks","Pain reduction at 4 weeks for wounds treated with ACTIGRAFT compared to other treatments (no ACTIGRAFT) for patients reporting any level of wound related pain (\\>1 on a VAS scale of 0-10 points) at baseline",{"allocation":27,"interventionModel":27,"interventionModelDescription":27,"primaryPurpose":27,"observationalModel":28,"timePerspective":29,"maskingInfo":27},null,"OTHER","PROSPECTIVE","Patients with all types of exuding cutaneous wound",[32],{"label":33,"type":27,"description":34,"interventionNames":35},"ActiGraft","Whole blood clot (WBC) gel",[36],"Device: ActiGraft",[38],{"type":39,"name":33,"description":34,"armGroupLabels":40,"otherNames":27},"DEVICE",[33],[42],{"name":43,"affiliation":5,"role":44},"Sharon Sirota","STUDY_DIRECTOR",[46],{"name":43,"role":47,"phone":48,"phoneExt":27,"email":49},"CONTACT","+972545800765","sharon@reddress.co.il",[51],{"facility":52,"status":53,"city":54,"state":55,"zip":56,"country":57,"countryCode":58,"cosmosGeoPoint":59,"geoPoint":64,"contacts":65},"Wound Care Experts","RECRUITING","Las Vegas","Nevada","89128","United States","US",{"type":60,"coordinates":61},"Point",[62,63],-115.13722,36.17497,{"lat":63,"lon":62},[66],{"name":67,"role":47,"phone":27,"phoneExt":27,"email":27},"Naz Wahab, M.D",{"type":69,"investigatorFullName":27,"investigatorTitle":27,"investigatorAffiliation":27,"oldNameTitle":27,"oldOrganization":27},"SPONSOR","100416180",false,"NCT04699305","Safety and Efficacy of ActiGraft Treatment in Wound Care in Medical Centers","An Observational Clinical Registry to Collect Safety and Efficacy Data on Wound Care in Medical Centers","Inclusion Criteria:\n\n* Subject is ≥18 years of age\n* Subject has an exuding cutaneous wound\n* Subject agrees to the use of his health data, including photos of his wound in analysis and publications\n* Subject\u002FLAR must be able to read and understand English and\u002For Spanish\n\nExclusion Criteria:\n\n* Subject\u002FLAR is unable to read and understand English or Spanish.","ALL","18 Years",{"count":79,"type":80},500,"ESTIMATED","1 Year","OBSERVATIONAL","Multicenter observational study to explore the efficacy of ActiGraft in the treatment of exuding cutaneous wounds in real-life usage.",[85],"Cutaneous Wounds",[87],"DFU, PU, Surgical, Vascular, Trauma","2025-07-28",{"date":90,"type":91},"2025-07-29","ACTUAL",{"date":93,"type":91},"2019-02-14",{"date":95,"type":80},"2027-01-31",{"name":5,"class":6},1]